{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:53:11Z","timestamp":1790779991659,"version":"4.1.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s13023-018-0759-9","type":"journal-article","created":{"date-parts":[[2018,1,30]],"date-time":"2018-01-30T07:24:40Z","timestamp":1517297080000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Common drug review recommendations for orphan drugs in Canada: basis of recommendations and comparison with similar reviews in Quebec, Australia, Scotland and New Zealand"],"prefix":"10.1186","volume":"13","author":[{"given":"John I.","family":"McCormick","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L. Diana","family":"Berescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nabil","family":"Tadros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,30]]},"reference":[{"key":"759_CR1","volume-title":"Drugs for rare diseases: evolving trends in regulatory and health technology assessment perspectives [environmental scan, issue 42]","author":"L Loorand-Stiver","year":"2013","unstructured":"Loorand-Stiver L. Drugs for rare diseases: evolving trends in regulatory and health technology assessment perspectives [environmental scan, issue 42]. Ottawa: Canadian Agency for Drugs and Technologies in. Health; 2013. \n                    http:\/\/www.cadth.ca\/media\/pdf\/ES0281_RareDiseaseDrugs_es_e.pdf\n                    \n                  . Accessed 20 Dec 2017"},{"key":"759_CR2","unstructured":"BIOTECanada. The Canadian rare disease therapies landscape: Bridging opportunity to reality. \n                    http:\/\/www.biotech.ca\/wp-content\/uploads\/2016\/03\/white_paper_mar_2.pdf\n                    \n                  . Accessed 20 Dec 2017."},{"key":"759_CR3","unstructured":"Canadian Institute of Health Research. New emerging team for rare diseases. \n                    http:\/\/rare-diseases.ca\/\n                    \n                  . Accessed 20 Dec 2017."},{"key":"759_CR4","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1093\/qjmed\/hci128","volume":"98","author":"DA Hughes","year":"2005","unstructured":"Hughes DA, Tunnage B, Yeo ST. Drugs for exceptionally rare diseases: do they deserve special status for funding? QJM. 2005;98:829\u201336.","journal-title":"QJM"},{"key":"759_CR5","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1017\/S0266462307051550","volume":"23","author":"MF Drummond","year":"2007","unstructured":"Drummond MF, Kanavos P, Ubel P, Rovira J. Assessing the economic challenges posed by orphan drugs. Int J Technol Assess Health Care. 2007;23:36\u201342.","journal-title":"Int J Technol Assess Health Care"},{"key":"759_CR6","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1503\/cmaj.050706","volume":"174","author":"JTR Clarke","year":"2006","unstructured":"Clarke JTR. Is the current approach to reviewing new drugs condemning the victims of rare disease to death? A call for a national orphan drug review policy. Can Med Assoc J. 2006;174:189\u201390.","journal-title":"Can Med Assoc J"},{"key":"759_CR7","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2165\/11539190-000000000-00000","volume":"29","author":"CR Blankart","year":"2011","unstructured":"Blankart CR, Stargardt T, Schreyogg J. Availability of and access to orphan drugs. An international comparison of pharmaceutical treatments for pulmonary arterial hypertension, fabry disease, hereditary angiodema and chronic myeloid leukemia. PharmacoEconomics. 2011;29:63\u201382.","journal-title":"PharmacoEconomics"},{"key":"759_CR8","doi-asserted-by":"publisher","first-page":"1651","DOI":"10.1016\/j.clinthera.2010.08.006","volume":"32","author":"S Vegter","year":"2010","unstructured":"Vegter S, Rozenbaum MH, Postema R, Tolley K, Postma MJ. Review of regulatory recommendations for orphan drug submissions in the Netherlands and Scotland: focus on the underlying pharmacoeconomic evaluations. Clin Ther. 2010;32:1651\u201361.","journal-title":"Clin Ther"},{"key":"759_CR9","doi-asserted-by":"publisher","first-page":"883","DOI":"10.2165\/11585980-000000000-00000","volume":"29","author":"A Denis","year":"2011","unstructured":"Denis A, Mergaert L, Fostier C, Cleemput I, Hulstaert F, Simoens S. Critical assessment of Belgian reimbursement dossiers of orphan drugs. PharmacoEconomics. 2011;29:883\u201393.","journal-title":"PharmacoEconomics"},{"key":"759_CR10","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1016\/j.jval.2012.09.004","volume":"15","author":"A Cote","year":"2012","unstructured":"Cote A, Keating B. What is wrong with orphan drug policies? Value Health. 2012;15:1185\u201391.","journal-title":"Value Health"},{"key":"759_CR11","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/1750-1172-6-42","volume":"6","author":"S Simoens","year":"2011","unstructured":"Simoens S. Pricing and reimbursement of orphan drugs: the need for more transparency. Orphanet J Rare Dis. 2011;6:42.","journal-title":"Orphanet J Rare Dis"},{"key":"759_CR12","doi-asserted-by":"publisher","first-page":"E787","DOI":"10.1503\/cmaj.081429","volume":"182","author":"AH Panju","year":"2010","unstructured":"Panju AH, Bell CM. Policy alternatives for treatments for rare diseases. Can Med Assoc J. 2010;182:E787\u201392.","journal-title":"Can Med Assoc J"},{"key":"759_CR13","unstructured":"House of Commons Debates. April 14, 2008; Treatment of rare disorders. \n                    http:\/\/www.parl.gc.ca\/HousePublications\/Publication.aspx?DocId=3419095&Language=E&Mode=1\n                    \n                  . Accessed 21 Dec 2017."},{"key":"759_CR14","first-page":"e42","volume":"21","author":"DK Lee","year":"2014","unstructured":"Lee DK, Wong B. An orphan drug framework (ODF) for Canada. J Popul Ther Clin Pharmacol. 2014;21:e42\u20136.","journal-title":"J Popul Ther Clin Pharmacol"},{"key":"759_CR15","first-page":"21","volume":"20","author":"D Wong-Rieger","year":"2013","unstructured":"Wong-Rieger D. Canada's long journey toward an orphan drug framework. Advocate. 2013;20:21. \n                    http:\/\/www.raredisorders.ca\/content\/uploads\/Orphan-Drug-Framework\n                    \n                  . pdf. Accessed 21 Dec 2017","journal-title":"Advocate"},{"key":"759_CR16","unstructured":"Benefits Canada. Health Canada puts the brakes on plan for orphan drug framework: \n                    http:\/\/www.benefitscanada.com\/news\/health-canada-puts-brakes-on-plan-for-orphan-drug-framework-105588\n                    \n                  . Accessed 7 Dec 2017."},{"key":"759_CR17","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1503\/cmaj.070713","volume":"178","author":"M Tierney","year":"2008","unstructured":"Tierney M, Manns B, with the members of the Canadian Expert Drug Advisory Committee. Optimizing the use of prescription drugs in Canada through the Common Drug Review. Can Med Assoc J. 2008;178:432\u20135.","journal-title":"Can Med Assoc J"},{"key":"759_CR18","unstructured":"Canadian Agency for Drugs and Technologies in Health. Procedure for CADTH Common Drug Review. \n                    https:\/\/www.cadth.ca\/media\/cdr\/process\/CDR_Procedure.pdf\n                    \n                  . Accessed 21 Dec 2017."},{"key":"759_CR19","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2165\/11593030-000000000-00000","volume":"30","author":"A Rocchi","year":"2012","unstructured":"Rocchi A, Miller E, Hopkins RB, Goeree R. Common drug review recommendations. An evidence base for expectations. PharmacoEconomics. 2012;30:229\u201346.","journal-title":"PharmacoEconomics"},{"key":"759_CR20","doi-asserted-by":"publisher","first-page":"888","DOI":"10.1016\/j.jval.2014.08.2673","volume":"17","author":"D Husereau","year":"2014","unstructured":"Husereau D, Dempster W, Blanchard A, Chambers J. Evolution of drug reimbursement in Canada: the pan-Canadian Pharmaceutical Alliance for new drugs. Value Health. 2014;17:888\u201394.","journal-title":"Value Health"},{"key":"759_CR21","unstructured":"Pan-Canadian Oncology Drug Review. \n                    https:\/\/www.cadth.ca\/about-cadth\/what-we-do\/products-services\/pcodr\n                    \n                  . Accessed 21 Dec 2017."},{"key":"759_CR22","unstructured":"The Rx&D International Report on access to medicines 2010\u20132011. \n                    http:\/\/www.wyatthealth.com\/wp-content\/uploads\/IRAM\/iram-2010-2011-English.pdf\n                    \n                  . Accessed 21 Dec 2017."},{"key":"759_CR23","doi-asserted-by":"publisher","first-page":"1437","DOI":"10.1001\/jama.2009.1409","volume":"302","author":"FM Clement","year":"2009","unstructured":"Clement FM, Harris A, Li JJ, Yong K, Lee KM, Manns BJ. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia and Canada. JAMA. 2009;302:1437\u201343.","journal-title":"JAMA"},{"key":"759_CR24","unstructured":"Standing Committee on Health. Prescription drugs-Part 1. The Common Drug Review: An F\/P\/T process. \n                    http:\/\/www.parl.gc.ca\/content\/hoc\/Committee\/392\/HESA\/Reports\/RP3162492\/hesarp02\/hesarp02-e.pdf\n                    \n                  . Accessed 21 Dec 2017."},{"key":"759_CR25","unstructured":"Recommendation framework for CADTH Common Drug Review and pan-Canadian Oncology Drug Review programs: Guidance for CADTH\u2019s Drug Expert Committee. March 2016. \n                    https:\/\/www.cadth.ca\/media\/cdr\/templates\/pre-sub-phase\/CDR_pCODR_recommendations_framework.pdf\n                    \n                  . Accessed: 21 Dec 2017."},{"key":"759_CR26","unstructured":"Tadros N, McCormick J. Towards a new way of evaluating orphan drugs at CADTH. \n                    http:\/\/www.orphan-drugs.org\/2017\/02\/23\/towards-new-way-evaluating-orphan-drugs-cadth\/\n                    \n                  . Accessed 21 Dec 2017."},{"key":"759_CR27","unstructured":"Orphanet: Orphan drug list. \n                    http:\/\/www.orpha.net\/consor\/cgi-bin\/Drugs_ListDrugs_List.php?lng=EN&TAG=A\n                    \n                  . Accessed 21 Dec 2017."},{"key":"759_CR28","unstructured":"Food and Drug Administration. Orphan Drug List. \n                    http:\/\/www.accessdata.fda.gov\/scripts\/opdlisting\/oopd\/index.cfm\n                    \n                  . Accessed 21 Dec 2017."},{"key":"759_CR29","unstructured":"CADTH Common Drug Review (CDR) Reports. \n                    https:\/\/www.cadth.ca\/about-cadth\/what-we-do\/products-services\/cdr\/reports\n                    \n                  . Accessed 21 Dec 2017."},{"key":"759_CR30","unstructured":"Scottish Medicines Consortium. \n                    http:\/\/www.scottishmedicines.org.uk\/\n                    \n                  . Accessed 21 Dec 2017."},{"key":"759_CR31","unstructured":"Scottish Medicines Consortium. PACE: Medicines for end of life and very rare conditions. \n                    http:\/\/www.scottishmedicines.org.uk\/Submission_Process\/Submission_guidance_and_forms\/PACE\n                    \n                  . Accessed 21 Dec 2017."},{"key":"759_CR32","unstructured":"Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee. \n                    http:\/\/www.pbac.pbs.gov.au\/\n                    \n                  . Accessed 21 Dec 2017."},{"key":"759_CR33","unstructured":"Life Savings Drug Program Criteria and Conditions. \n                    http:\/\/www.health.gov.au\/internet\/main\/publishing.nsf\/Content\/lsdp-criteria\n                    \n                  . Accessed 21 Dec 2017."},{"key":"759_CR34","unstructured":"PBAC Guidelines. F.3 Other relevant factors. \n                    https:\/\/pbac.pbs.gov.au\/content\/information\/archived-versions\/pbac-guidelines-v4-5.pdf\n                    \n                  . Accessed July 2015."},{"key":"759_CR35","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.healthpol.2010.09.008","volume":"100","author":"ZRS Rosenberg-Yunger","year":"2011","unstructured":"Rosenberg-Yunger ZRS, Daar AS, Thorsteinsdottir H, Martin KM. Priority setting for orphan drugs: an international comparison. Health Policy. 2011;100:25\u201334.","journal-title":"Health Policy"},{"key":"759_CR36","unstructured":"PHARMAC. Pharmaceutical Management Agency: \n                    https:\/\/www.pharmac.govt.nz\n                    \n                  \/. Accessed 21 Dec 2017."},{"key":"759_CR37","first-page":"12","volume":"124","author":"M Wonder","year":"2011","unstructured":"Wonder M, Milne R. Access to new medicines in New Zealand compared to Australia. N Z Med J. 2011;124:12\u201328.","journal-title":"N Z Med J"},{"key":"759_CR38","unstructured":"PHARMAC. High cost medicines for rare diseases. Discussion document and a request for your input. \n                    http:\/\/www.pharmac.health.nz\/assets\/high-cost-medicines-discussion-document-2014-04.pdf\n                    \n                  . Accessed 21 Dec 2017."},{"key":"759_CR39","unstructured":"PHARMAC\u2019s Decision Criteria. Proposal for change. February 2014. \n                    http:\/\/www.pharmac.health.nz\/assets\/consultation-2014-02-19-dcc.pdf\n                    \n                  . Accessed 21 Dec 2017."},{"key":"759_CR40","unstructured":"PHARMAC. Medicines for rare disorders: \n                    http:\/\/www.pharmac.govt.nz\/medicines\/how-medicines-are-funded\/medicines-for-rare-disorders\/\n                    \n                  . Accessed 21 Dec 2017."},{"key":"759_CR41","unstructured":"Institut national d\u2019excellence en sant\u00e9 et en services sociaux (INESSS). \n                    https:\/\/www.inesss.qc.ca\/en.html\n                    \n                  . Accessed 21 Dec 2017."},{"issue":"6","key":"759_CR42","first-page":"1","volume":"7","author":"Institut national d\u2019excellence en sant\u00e9 et services sociaux (INESSS)","year":"2011","unstructured":"Institut national d\u2019excellence en sant\u00e9 et services sociaux (INESSS). Prise en charge des maladies rares : Exp\u00e9riences \u00e9trang\u00e8res. Rapport pr\u00e9par\u00e9 par St\u00e9phanie Elger. ETMIS. 2011;7(6):1\u201363.","journal-title":"ETMIS"},{"key":"759_CR43","unstructured":"Scottish Medicines Consortium. SMC Advice Directory: \n                    http:\/\/www.scottishmedicines.org.uk\/SMC_Advice\/Advice_Directory\/SMC_Advice_Directory\n                    \n                  . Accessed 21 Dec 2017."},{"key":"759_CR44","unstructured":"Australian Government. Department of Health. Public summary documents by product. \n                    http:\/\/www.pbs.gov.au\/info\/industry\/listing\/elements\/pbac-meetings\/psd\/public-summary-documents-by-product\n                    \n                  . Accessed 21 Dec 2017."},{"key":"759_CR45","unstructured":"PHARMAC Pharmaceutical Management Agency. Application Tracker. \n                    http:\/\/www.pharmac.govt.nz\/patients\/ApplicationTracker\n                    \n                  . Accessed 21 Dec 2017."},{"key":"759_CR46","unstructured":"INESSS: Drug products undergoing evaluation and evaluated: \n                    https:\/\/www.inesss.qc.ca\/en\/activities\/drug-products\/drug-products-undergoing-evaluation-and-evaluated.html\n                    \n                  . Accessed 21 Dec 2017."},{"key":"759_CR47","unstructured":"R\u00e9gie de l'assurance maladie du Qu\u00e9bec. List of Medications : \n                    http:\/\/www.ramq.gouv.qc.ca\/SiteCollectionDocuments\/liste_med\/liste_med_2017_03_22_en.pdf\n                    \n                  . Accessed 21 Dec 2017."},{"key":"759_CR48","volume-title":"Practical statistics for medical research","author":"DG Altman","year":"1991","unstructured":"Altman DG. Practical statistics for medical research. London: Chapman and Hall; 1991."},{"key":"759_CR49","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1186\/s13023-016-0539-3","volume":"11","author":"G Janoudi","year":"2016","unstructured":"Janoudi G, Amegatse W, McIntosh B, Sehgal C, Richter T. Health technology assessment of drugs for rare diseases: insights, trends, and reasons for negative recommendations from the CADTH Common Drug Review. Orphanet J Rare Dis. 2016;11:164.","journal-title":"Orphanet J Rare Dis"},{"key":"759_CR50","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1111\/j.1365-2125.2010.03877.x","volume":"71","author":"AG Dupont","year":"2011","unstructured":"Dupont AG, Van Wilder PB. Access to orphan drugs despite poor quality of clinical evidence. Br J Clin Pharmacol. 2011;71:488\u201396.","journal-title":"Br J Clin Pharmacol"},{"key":"759_CR51","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13023-017-0611-7","volume":"12","author":"NSB Rawson","year":"2017","unstructured":"Rawson NSB. Health technology assessment of new drugs for rare disorders in Canada: impact of disease prevalence and cost. Orphanet J Rare Dis. 2017;12:59.","journal-title":"Orphanet J Rare Dis"},{"key":"759_CR52","doi-asserted-by":"publisher","first-page":"A6","DOI":"10.1016\/j.jval.2014.03.040","volume":"17","author":"D Liden","year":"2014","unstructured":"Liden D, Jaksa A, Daniel K, Ho Y. CADTH recommendations as predictors for drug availability in British Columbia and Ontario. Value Health. 2014;17:A6.","journal-title":"Value Health"},{"key":"759_CR53","doi-asserted-by":"publisher","first-page":"E674","DOI":"10.9778\/cmajo.20160006","volume":"4","author":"N Allen","year":"2016","unstructured":"Allen N, Walker SR, Liberti L, Sehgal C, Salek MS. Evaluating alignment between Canadian Common Drug Review reimbursement recommendations and provincial drug plan listing decisions: an exploratory study. CMAJ Open. 2016;4:E674\u20138.","journal-title":"CMAJ Open"},{"key":"759_CR54","first-page":"15","volume":"11","author":"D Menon","year":"2015","unstructured":"Menon D, Clark D, Stafinski T. Reimbursement of drugs for rare diseases through the public healthcare system in Canada: where are we now? Healthc Policy. 2015;11:15\u201332.","journal-title":"Healthc Policy"},{"key":"759_CR55","first-page":"581","volume":"14","author":"J Lexchin","year":"2008","unstructured":"Lexchin J, Mintzes B. Medicine reimbursement recommendations in Canada, Australia and Scotland. Am J Manag Care. 2008;14:581\u20138.","journal-title":"Am J Manag Care"},{"key":"759_CR56","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1016\/j.jval.2016.10.014","volume":"20","author":"N Allen","year":"2017","unstructured":"Allen N, Walker SR, Liberti L, Salek S. Health technology assessment (HTA) case studies: factors influencing divergent HTA reimbursement recommendations in Australia, Canada, England and Scotland. Value Health. 2017;20:320\u20138.","journal-title":"Value Health"},{"key":"759_CR57","doi-asserted-by":"publisher","first-page":"327","DOI":"10.2147\/CEOR.S134230","volume":"9","author":"EM Adkins","year":"2017","unstructured":"Adkins EM, Nicholson L, Floyd D, Ratcliffe M, Chevrou-Severac H. Oncology drugs for orphan indications: how are HTA processes evolving for this specific drug category? Clinicoecon Outcomes Res. 2017;9:327\u201342.","journal-title":"Clinicoecon Outcomes Res"},{"key":"759_CR58","doi-asserted-by":"publisher","first-page":"A28","DOI":"10.1016\/j.jval.2014.03.172","volume":"17","author":"F Mills","year":"2014","unstructured":"Mills F, Poinas AC, Siu E, Wyatt G. Consistency in reimbursement decisions at Canadian HTA agencies: INESSS versus CDR. Value Health. 2014;17:A28.","journal-title":"Value Health"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-018-0759-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T19:53:15Z","timestamp":1548791595000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-018-0759-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,30]]},"references-count":58,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["759"],"URL":"https:\/\/doi.org\/10.1186\/s13023-018-0759-9","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,30]]},"assertion":[{"value":"7 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 January 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"NT and JMC are employees of McKesson Canada and have no additional competing interests. LDB has no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"27"}}